Diabetes Duration and Subclinical Myocardial Injury: The Atherosclerosis Risk in Communities Study (ARIC).


Journal

Clinical chemistry
ISSN: 1530-8561
Titre abrégé: Clin Chem
Pays: England
ID NLM: 9421549

Informations de publication

Date de publication:
06 10 2022
Historique:
received: 24 03 2022
accepted: 09 06 2022
pubmed: 30 7 2022
medline: 12 10 2022
entrez: 29 7 2022
Statut: ppublish

Résumé

Diabetes exerts adverse effects on the heart, and a longer diabetes duration is associated with greater heart failure risk. We studied diabetes duration and subclinical myocardial injury, as reflected by high-sensitivity cardiac troponin (hs-cTnT). We analyzed 9052 participants without heart failure or coronary heart disease (mean age 63 years, 58% female, 21% Black, 15% with diabetes) at The Atherosclerosis Risk in Communities Study (ARIC) Visit 4 (1996 to 1998). Diabetes duration was calculated based on diabetes status at Visits 1 (1987 to 1989) through 4, or using self-reported age of diabetes diagnosis prior to Visit 1. We used multinomial logistic regression to determine the association of diabetes duration with increased (≥14 ng/L) or detectable (≥6 ng/L) Visit 4 hs-cTnT, relative to undetectable hs-cTnT, adjusted for demographics and cardiovascular risk factors. The prevalence of increased Visit 4 hs-cTnT was higher in persons with longer diabetes duration, from 12% for those with diabetes 0 to <5 years up to 31% among those with diabetes for ≥15 years (P for trend <0.0001). New onset diabetes at Visit 4 was associated with 1.92× higher relative risk (95% CI, 1.27-2.91) of increased hs-cTnT than no diabetes. Longer diabetes duration was associated with greater myocardial injury, with duration ≥15 years associated with 9.29× higher risk (95% CI, 5.65-15.29) for increased hs-cTnT and 2.07× (95% CI, 1.24-3.16) for detectable hs-cTnT, compared to no diabetes. Longer diabetes duration is strongly associated with subclinical myocardial injury. Interventional studies are needed to assess whether the prevention and delay of diabetes onset can mitigate early myocardial damage.

Sections du résumé

BACKGROUND
Diabetes exerts adverse effects on the heart, and a longer diabetes duration is associated with greater heart failure risk. We studied diabetes duration and subclinical myocardial injury, as reflected by high-sensitivity cardiac troponin (hs-cTnT).
METHODS
We analyzed 9052 participants without heart failure or coronary heart disease (mean age 63 years, 58% female, 21% Black, 15% with diabetes) at The Atherosclerosis Risk in Communities Study (ARIC) Visit 4 (1996 to 1998). Diabetes duration was calculated based on diabetes status at Visits 1 (1987 to 1989) through 4, or using self-reported age of diabetes diagnosis prior to Visit 1. We used multinomial logistic regression to determine the association of diabetes duration with increased (≥14 ng/L) or detectable (≥6 ng/L) Visit 4 hs-cTnT, relative to undetectable hs-cTnT, adjusted for demographics and cardiovascular risk factors.
RESULTS
The prevalence of increased Visit 4 hs-cTnT was higher in persons with longer diabetes duration, from 12% for those with diabetes 0 to <5 years up to 31% among those with diabetes for ≥15 years (P for trend <0.0001). New onset diabetes at Visit 4 was associated with 1.92× higher relative risk (95% CI, 1.27-2.91) of increased hs-cTnT than no diabetes. Longer diabetes duration was associated with greater myocardial injury, with duration ≥15 years associated with 9.29× higher risk (95% CI, 5.65-15.29) for increased hs-cTnT and 2.07× (95% CI, 1.24-3.16) for detectable hs-cTnT, compared to no diabetes.
CONCLUSIONS
Longer diabetes duration is strongly associated with subclinical myocardial injury. Interventional studies are needed to assess whether the prevention and delay of diabetes onset can mitigate early myocardial damage.

Identifiants

pubmed: 35904048
pii: 6650408
doi: 10.1093/clinchem/hvac117
pmc: PMC9766881
mid: NIHMS1849701
doi:

Substances chimiques

Biomarkers 0
Troponin T 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1272-1280

Subventions

Organisme : NHLBI NIH HHS
ID : K24 HL152440
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92022D00003
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700002I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700005I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700003I
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL146907
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK089174
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700001I
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007024
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201700004I
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© American Association for Clinical Chemistry 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Eur J Heart Fail. 2021 Mar;23(3):352-380
pubmed: 33605000
J Am Heart Assoc. 2017 Jul 17;6(7):
pubmed: 28716801
Nutr Metab Cardiovasc Dis. 2018 Nov;28(11):1081-1091
pubmed: 30318112
Circ Res. 2020 May 22;126(11):1501-1525
pubmed: 32437308
Circulation. 2011 Apr 5;123(13):1367-76
pubmed: 21422391
Clin Chem. 2010 Feb;56(2):254-61
pubmed: 19959623
JAMA. 2010 Dec 8;304(22):2494-502
pubmed: 21078811
Circulation. 2015 Jul 28;132(4):269-77
pubmed: 26022911
Am J Epidemiol. 1993 Jun 15;137(12):1328-40
pubmed: 8333414
J Am Coll Cardiol. 2021 Jun 15;77(23):2939-2959
pubmed: 34112321
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Circulation. 2014 Oct 14;130(16):1374-82
pubmed: 25149362
J Am Coll Cardiol. 2010 Jan 26;55(4):283-93
pubmed: 20117431
Diabetes Care. 2018 Apr;41(4):731-738
pubmed: 29317451
JACC Heart Fail. 2021 Aug;9(8):594-603
pubmed: 34325890
Clin Chem. 2018 Jan;64(1):201-209
pubmed: 29158254
JACC Heart Fail. 2014 Dec;2(6):600-7
pubmed: 25443112
Exp Physiol. 1997 May;82(3):423-52
pubmed: 9179565
Circulation. 2022 May 3;145(18):e895-e1032
pubmed: 35363499
Curr Heart Fail Rep. 2017 Aug;14(4):301-310
pubmed: 28639234
J Am Coll Cardiol. 2010 Sep 28;56(14):1071-8
pubmed: 20863950
J Am Coll Cardiol. 2012 Jan 31;59(5):484-9
pubmed: 22281251
J Am Coll Cardiol. 2003 Apr 16;41(8):1387-93
pubmed: 12706936
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978

Auteurs

Carine E Hamo (CE)

Division of Cardiology, Johns Hopkins University, Baltimore, MD, USA.

Justin B Echouffo-Tcheugui (JB)

Department of Endocrinology, Johns Hopkins University, Baltimore, MD, USA.

Sui Zhang (S)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Roberta Florido (R)

Division of Cardiology, Johns Hopkins University, Baltimore, MD, USA.

James S Pankow (JS)

Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA.

Erin D Michos (ED)

Division of Cardiology, Johns Hopkins University, Baltimore, MD, USA.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Ronald Goldberg (R)

Division of Endocrinology, University of Miami, Miami, FL, USA.

Vijay Nambi (V)

Michael E DeBakey Veterans Affairs Hospital, Houston TX, USA.
Division of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.

Gary Gerstenblith (G)

Division of Cardiology, Johns Hopkins University, Baltimore, MD, USA.

Wendy S Post (WS)

Division of Cardiology, Johns Hopkins University, Baltimore, MD, USA.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Roger S Blumenthal (RS)

Division of Cardiology, Johns Hopkins University, Baltimore, MD, USA.

Christie Ballantyne (C)

Division of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX, USA.

Elizabeth Selvin (E)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Josef Coresh (J)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Chiadi E Ndumele (CE)

Division of Cardiology, Johns Hopkins University, Baltimore, MD, USA.
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH